drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Humanized IgG1 monoclonal antibody targeting SLAMF7 (CS1) on myeloma and NK cells; enhances NK cell–mediated ADCC and immune activation.
nci_thesaurus_concept_id
C66982
nci_thesaurus_preferred_term
Elotuzumab
nci_thesaurus_definition
A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.
drug_mesh_term
Elotuzumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 monoclonal antibody targeting SLAMF7 (CS1) on myeloma and NK cells; promotes antibody-dependent cellular cytotoxicity (ADCC) against SLAMF7+ myeloma cells via Fcγ receptor engagement and directly activates NK cells through SLAMF7 signaling to enhance immune-mediated tumor killing.
drug_name
Elotuzumab
nct_id_drug_ref
NCT05981209